You are on page 1of 5

OC DISCUSSIONS (PULMO)

1. HOW DO YOU MANAGE MODERATE TO SEVERE PNEUMONIA?


2. WHAT FACTORS DO YOU CONSIDER IN SELECTING THE ORAL
ROUTE OVER THE IV ROUTE ESPECIALLY IN GIVING
LEVOFLOXACIN?
3. HOW MANY DAYS ON THE AVERAGE DO YOU USUALLY SWITCH
PATIENTS FROM IV TO ORAL?
4. WHAT ARE OTHER RTIS WHERE YOU CONSIDER
LEVOFLOXACIN?
5. WHAT IS IT ABOUT LEVOFLOXACIN THAT YOU LIKE ABOUT?

NOTES:
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
OC DISCUSSIONS (IDS)
1. DOES THE HOSPITAL HAVE AN ANTIBIOGRAM AND HOW
OFTEN IS THIS UPDATED IN A YEAR?
2. WHICH SEVERE INFECTIOUS CASES HAVE HIGH INCIDENCE IN
THIS HOSPITAL?
3. WHAT ARE THE MICROORGANISMS WITH HIGH RATES OF
RESISTANCE THAT ARE PREVALENT IN THE HOSPITAL?
4. WHAT IS THE PROTOCOL IN GIVING LEVOFLOXACIN IN THIS
HOSPITAL?
NOTES:
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
ICU PROGRAM

1. WERE YOU ABLE TO ENCOUNTER SEVERE INFECTIONS WHERE YOU


WERE ABLE TO USE MEROPENEM, AND PIPERACILLIN +
TAZOBACTAM THIS MONTH?
2. WHAT IS THE DISEASE AND ITS PATHOPHYSIOLOGY?
3. WHAT IS THE PROGNOSIS OF THE CASE YOU ENCOUNTERED AND
HOW DID YOU MANAGE IT?
NOTES:
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
TAKE NOTE: PROVIDE IDSA GUIDELINES DEPENDING ON THE NATURE OF
CASES ENCOUNTERED BY ICU RESIDENTS
AGAHAN, TANGHALIAN,
MERYENDA

1. WERE YOU ABLE TO ENCOUNTER SEVERE INFECTIONS WHERE YOU


WERE ABLE TO USE MEROPENEM, AND PIPERACILLIN +
TAZOBACTAM THIS MONTH?
2. WHAT IS THE DISEASE AND ITS PATHOPHYSIOLOGY?
3. WHAT IS THE PROGNOSIS OF THE CASE YOU ENCOUNTERED AND
HOW DID YOU MANAGE IT?
NOTES:
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
TAKE NOTE: PROVIDE IDSA GUIDELINES DEPENDING ON THE NATURE OF
CASES ENCOUNTERED BY ICU RESIDENTS
ASK THE MENTOR
1. HOW DO YOU READ A HOSPITAL ANTIBIOGRAM?
2. HOW COULD THE ANTIBIOGRAM AFFECT YOUR CLINICAL
JUDGMENT IN TERMS OF EMPIRIC TREATMENT?
3. HOW DOES GUIDELINES MATTER IN THE MANAGEMENT
OF INFECTIONS?
NOTES:
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________

You might also like